A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.
← catalyst calendarNCT07448623 · readout in 284 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
14estimated
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-02 | actual | When the study began enrolling |
| Primary completion | 2027-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-25 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloid Cardiomyopathy
Intervention
- Drug: Coramitug
Primary outcomes
what the primary-completion date above is the date OFMean Standard Uptake Value Ratio (SUVRmean) in myocardium
measured Day 1-day 8
Net uptake rate constant (Ki) in myocardium
measured 0 to 168 hours
Change in SUVRmean in myocardium
measured From baseline to week 52 (day 364), or week 60 (day 420) if there is no uptake expected/observed when both unradiolabelled and radiolabelled compounds are administered together
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed